Sjögren's syndrome: a systemic autoimmune disease
S Negrini, G Emmi, M Greco, M Borro… - Clinical and …, 2022 - Springer
Sjögren's syndrome is a chronic autoimmune disease characterized by ocular and oral
dryness resulting from lacrimal and salivary gland dysfunction. Besides, a variety of systemic …
dryness resulting from lacrimal and salivary gland dysfunction. Besides, a variety of systemic …
Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern …
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and …
GC Drosos, D Vedder, E Houben, L Boekel… - Annals of the …, 2022 - ard.bmj.com
Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
A Dima, C Jurcut, F Chasset… - Therapeutic …, 2022 - journals.sagepub.com
The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies
M Ramos-Casals, P Brito-Zerón… - Annals of the …, 2020 - ard.bmj.com
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in
recent decades: treatment decisions remain challenging in clinical practice, without a …
recent decades: treatment decisions remain challenging in clinical practice, without a …
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised …
Background Azathioprine is used as a first-line treatment to prevent relapses of
neuromyelitis optica spectrum disorder (NMOSD). Tocilizumab has been reported to reduce …
neuromyelitis optica spectrum disorder (NMOSD). Tocilizumab has been reported to reduce …
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies
GE Thorlacius, A Björk… - Nature Reviews …, 2023 - nature.com
In primary Sjögren syndrome (pSS), chronic inflammation of exocrine glands results in tissue
destruction and sicca symptoms, primarily of the mouth and eyes. Fatigue, arthralgia and …
destruction and sicca symptoms, primarily of the mouth and eyes. Fatigue, arthralgia and …
Current and future therapies for primary Sjögren syndrome
R Seror, G Nocturne, X Mariette - Nature Reviews Rheumatology, 2021 - nature.com
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that is characterized by
a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic …
a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic …
Current state of knowledge on primary Sjögren's syndrome, an autoimmune exocrinopathy
Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune rheumatic disease
characterized by lymphoplasmacytic infiltration of the salivary and lacrimal glands, whereby …
characterized by lymphoplasmacytic infiltration of the salivary and lacrimal glands, whereby …
[HTML][HTML] Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies… - Annals of oncology, 2020 - Elsevier
Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …